Press releases

Eevia Health Plc - Notification of management's transactions

Eevia Health Plc has received the following notification pursuant to Article 19 of the Market Abuse Regulation:

____________________________________________

Person subject to the notification requirement

Name: Nurmi-Aro, Kim

Position: Chief Financial Officer

Issuer: Eevia Health Plc

LEI: 743700NO7D0UA8J1MQ31

Notification type: INITIAL NOTIFICATION

Reference number: 743700NO7D0UA8J1MQ31_20210621133215_4

____________________________________________

Transaction date: 2021-06-17

Venue: SPOTLIGHT (XSAT)

Instrument type: SHARE

ISIN: FI4000496658

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 13,200 Unit price: 0.745 EUR

Aggregated transactions

(1): Volume: 13,200 Volume weighted average price: 0.745 EUR

For more information, please contact: 

Kim Nurmi-Aro, CFO

kim@eeviahealth.com

Tel.: +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. The Company addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts, which have scientifically documented health benefits, are sold B2B as ingredients to dietary supplements and food brands globally.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

2022-05-11
Regulatory

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

2022-03-15
Regulatory

Eevia Health Plc ("Eevia" or "The Company") is welcoming Gabriella Beni as our new Chief Financial Officer. Kim Nurmi-Aro will leave the Company on March 16th and the Company wishes him the very best in his new professional endeavors close to his home in the city of Vaasa. Gabriella Beni will take over the position on March 17th.

2022-03-09
Regulatory

Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market.

2021-11-16
Regulatory

The Board and CEO of Eevia Health Plc now present the Interim Report for the third quarter of 2021, covering the period 1 July through 30 September 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com

2021-11-12
Regulatory

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.

2021-11-11
Regulatory

This is a correction to press release published 10 November, 2021 where the press release lacked a reference to the EU's Market Abuse Regulation (MAR).

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.

1
2